Laboratory of Genetics and Molecular Cardiology (LIM13) (M.T.T., I.R.L., T.G.M.O., C.E.J., J.E.K., A.C.P.), University of São Paulo Medical School Hospital.
Lipid Clinic, Heart Institute (InCor) (V.Z.R., A.P.C., M.H.M., R.D.S.), University of São Paulo Medical School Hospital.
Circ Genom Precis Med. 2022 Jun;15(3):e003390. doi: 10.1161/CIRCGEN.121.003390. Epub 2022 May 12.
Sitosterolemia is a rare autosomal recessive disorder caused by homozygous or compound heterozygous variants in . The disease is characterized by increased plasma plant sterols. Small case series suggest that patients with sitosterolemia have wide phenotypic heterogeneity with great variability on either plasma cholesterol levels or development of atherosclerotic cardiovascular disease. The present study aims to characterize the prevalence and clinical features of sitosterolemia participating in a familial hypercholesterolemia genetic cascade screening program.
From 443 familial hypercholesterolemia index cases, 260 were negative for familial hypercholesterolemia genes and were sequenced for the genes. Clinical and laboratory characteristics of affected individuals were determined.
Eight (3.1%) index cases were found to be homozygous or compound heterozygous variant for genes, confirming the genetic diagnosis of sitosterolemia. Screening their relatives led to the identification of 6 additional confirmed sitosterolemia cases (3 homozygous and 3 compound heterozygous variant) and 18 carriers (heterozygous). The mean age of identified sitosterolemia cases (n=14) was 37.2±19.8 years, 50% were females, and 78.6% (all adults) presented either clinical or subclinical atherosclerotic cardiovascular disease. As expected, affected individuals presented elevated plasma plant sterol levels (mean β-Sitosterol and campesterol, respectively, 160.3±107.1 and 32.0±19.6 µg/mL) and the highest plasma LDL (low-density lipoprotein)-cholesterol was 269.0±120.0 mg/dL (range: 122-521 mg/dL). LDL-cholesterol mean reduction with therapy among cases was 65%. Eighty-three percent (83%) of identified sitosterolemia patients presented hematologic abnormalities.
Testing genes associated with sitosterolemia in the molecular routine workflow of a familial hypercholesterolemia cascade screening program allowed the precise diagnosis of sitosterolemia in a substantial number of patients with varying LDL-C levels and high incidence of early atherosclerotic cardiovascular disease and hematologic abnormalities.
甾醇血症是一种罕见的常染色体隐性遗传疾病,由 基因的纯合子或复合杂合变体引起。该疾病的特征是血浆植物固醇增加。小病例系列研究表明,甾醇血症患者具有广泛的表型异质性,血浆胆固醇水平或动脉粥样硬化性心血管疾病的发展变化很大。本研究旨在描述参与家族性高胆固醇血症遗传级联筛查计划的甾醇血症患者的患病率和临床特征。
从 443 例家族性高胆固醇血症索引病例中,有 260 例排除了家族性高胆固醇血症基因,对 基因进行了测序。确定了受影响个体的临床和实验室特征。
发现 8 例(3.1%)索引病例为 基因的纯合子或复合杂合变体,证实了甾醇血症的遗传诊断。对其亲属进行筛查,发现了另外 6 例确诊的甾醇血症病例(3 例纯合子和 3 例复合杂合变体)和 18 例携带者(杂合子)。确定的甾醇血症病例(n=14)的平均年龄为 37.2±19.8 岁,50%为女性,78.6%(均为成年人)存在临床或亚临床动脉粥样硬化性心血管疾病。正如预期的那样,受影响的个体表现出升高的血浆植物固醇水平(分别为β-谷固醇和菜油固醇的平均水平,分别为 160.3±107.1 和 32.0±19.6 µg/mL)和最高的血浆低密度脂蛋白(LDL)-胆固醇为 269.0±120.0 mg/dL(范围:122-521 mg/dL)。病例治疗后的 LDL-胆固醇平均降低了 65%。83%(83%)的确诊甾醇血症患者存在血液学异常。
在家族性高胆固醇血症级联筛查计划的分子常规工作流程中检测与甾醇血症相关的基因,可在 LDL-C 水平不同、早期动脉粥样硬化性心血管疾病发病率高且血液学异常发生率高的大量患者中精确诊断甾醇血症。